The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 with Adebrelimab with or without other Antitumor Therapy in Advanced or Metastatic Non-small cell lung Cancer.
To explore the reasonable dosage of SHR-A2102 for Advanced or Metastatic Non-small cell lung Cancer
Have the ability to give informed consent, have signed informed and able to comply with the treatment plan to visit the tests and other procedural requirements.
The age of signing the informed consent is 18 -70 years, regardless of gender.
Provide archived or fresh tumor tissue for vendor test.
At least one measurable lesion according to RECIST v1.1 criteria.
Active or symptomatic brain metastases.
With the exception of patients diagnosed with any other malignancy, except those who have achieved complete remission at least 5 years prior to screening and have ended adjuvant therapy, can be treated locally and have a clear medical record of cure, such as basal cell or squamous cell carcinoma of the skin, superficial bladder cancer in situ, carcinoma in situ of the cervix, breast ductal carcinoma in situ, and papillary carcinoma of the thyroid.
Uncontrollable moderate to large amounts of pleural effusion, peritoneal effusion or pericardial effusion.
Patients with uncontrolled tumor-related pain .